Pharmafile Logo
Pharmafocus logo
Advanced Search

Greece

Showing 14 posts of 14 posts found.

Novartis agrees to pay $347 million to settle bribery allegations

June 26, 2020
Medical Communications Greece, Novartis, bribery

Novartis and its former eye care unit Alcon have agreed to pay a combined $347 million to resolve allegations that …

News
greek_parliament

Investigation of kickbacks in Greece sputters to halt

May 21, 2018
Sales and Marketing Greece, Novartis, biotech, drugs, pharma, pharmaceutical

Greek parliament has decided against investigating allegations of bribery, involving Novartis and numerous high-level former politicians. The case has dominated …

News
greek_parliament

Greek parliament moves to investigate 10 politicians

February 22, 2018
Medical Communications, Sales and Marketing Greece, Greek Parliament, Novartis, biotech, drugs, pharma, pharmaceutical

After a 20-hour debate, Greek parliament has voted in favour of investigating 10 politicians named as part of an investigation …

News

Two former Greek PMs implicated in Novartis bribery case

February 6, 2018
Manufacturing and Production, Medical Communications Greece, Novartis, biotech, drugs, pharma, pharmaceutical

An ongoing investigated case into Novartis sales practices in Greece has so far implicated 10 current and former politicians. The …

News
novartis_window

Greek authorities raid Novartis’ offices after bribery allegations

January 4, 2017
Medical Communications, Research and Development Greece, Greek, Novartis, bribery

The investigation into practices by Novartis in its Greek operations has been accelerated after the attempted suicide of a Greek …

News
Witty image

Witty warns EU leaders over pricing

June 27, 2012
Sales and Marketing EFPIA, EU, GSK, Greece, R&D, Witty, pricing

Sir Andrew Witty has waded into the debate over Europe’s economic future with a plea for pharma innovation to be …

News

Europe’s pharma sector : living through the crisis

March 14, 2012
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Greece, Tonarelli, Witty, austerity, pharma

Pharmaceutical markets across Europe have been badly hit by the economic crisis, with revenues in some countries being decimated by …

Feature

Greek debt hits pharma deliveries

June 29, 2011
Sales and Marketing Greece

The debt crisis afflicting Greece is starting to affect the country’s hospitals as pharma companies refuse to deliver drugs. Roche …

News

Greece to cut 4,000 drug prices by a fifth

September 8, 2010
Sales and Marketing Greece, economic climate, price cuts, pricing & Reimbursement

The Greek government has released a list of over 4,000 drugs on which it will impose heavy price cuts. This …

News

Greece set for further price cuts

August 23, 2010
Sales and Marketing Greece

The Greek government is set to impose price cuts of more than 10% and will further cut reimbursement for a …

News
Andrew Witty

Let’s avoid further stand-offs, says Witty

June 22, 2010
Research and Development, Sales and Marketing EFPIA, Greece, industry, pricing

Pharma will need to find new ways of working with European governments in order to avoid further crises as witnessed …

News

Novo agrees price cut deal with Greece

June 16, 2010
Sales and Marketing Greece, Novo Nordisk, insulin, pricing

Novo Nordisk has agreed to resume supply of its insulins to the Greek market after pulling them last month as …

News

Novo withdraws insulins in Greece price protest

May 31, 2010
Sales and Marketing Greece, pricing

Insulin manufacturer Novo Nordisk says it will withdraw its modern insulin products from Greece in protest at a 25% price …

News

Greece’s crisis could hit European prices

May 6, 2010
Sales and Marketing Greece, industry, parallel trade, prices

GlaxoSmithKline’s chief executive Andrew Witty has warned that the economic crisis in Greece could have a knock-on effect across Europe, …

News

Latest content

GSK shares data from global shingles survey

December 1, 2023

AbbVie to acquire ImmunoGen for approximately $10.1bn

December 1, 2023

FDA accepts NDA for Karuna’s schizophrenia treatment

November 30, 2023

Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device

November 30, 2023

Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance

November 29, 2023